Marshall Wace LLP Acquires 293,004 Shares of Insmed Incorporated (NASDAQ:INSM)

Marshall Wace LLP raised its stake in shares of Insmed Incorporated (NASDAQ:INSM - Free Report) by 38.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,064,215 shares of the biopharmaceutical company's stock after acquiring an additional 293,004 shares during the quarter. Marshall Wace LLP owned approximately 0.59% of Insmed worth $73,473,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Steward Partners Investment Advisory LLC grew its stake in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC raised its position in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 248 shares in the last quarter. Spire Wealth Management bought a new stake in Insmed during the fourth quarter valued at $47,000. Smartleaf Asset Management LLC boosted its holdings in shares of Insmed by 98.1% in the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company's stock valued at $57,000 after buying an additional 411 shares during the period. Finally, Venturi Wealth Management LLC bought a new stake in shares of Insmed during the 4th quarter valued at about $86,000.

Insider Activity at Insmed

In other news, CEO William Lewis sold 6,830 shares of the company's stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $70.16, for a total transaction of $479,192.80. Following the completion of the sale, the chief executive officer now owns 233,924 shares in the company, valued at approximately $16,412,107.84. This represents a 2.84 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the transaction, the insider now directly owns 97,083 shares in the company, valued at $7,766,640. The trade was a 48.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 471,797 shares of company stock valued at $37,621,239. Insiders own 3.00% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently commented on INSM. HC Wainwright reaffirmed a "buy" rating and set a $90.00 target price on shares of Insmed in a report on Tuesday. Stifel Nicolaus reduced their price target on shares of Insmed from $97.00 to $96.00 and set a "buy" rating for the company in a report on Friday, February 21st. Wells Fargo & Company boosted their target price on shares of Insmed from $85.00 to $107.00 and gave the company an "overweight" rating in a research note on Wednesday, February 19th. UBS Group lifted their target price on Insmed from $105.00 to $110.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Finally, Royal Bank of Canada reissued an "outperform" rating and set a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $94.00.

Insmed Trading Up 1.9 %

Shares of NASDAQ:INSM traded up $1.32 during mid-day trading on Tuesday, hitting $70.83. The stock had a trading volume of 437,173 shares, compared to its average volume of 2,252,146. The company has a market cap of $12.88 billion, a PE ratio of -12.68 and a beta of 1.07. The company's 50 day moving average is $75.14 and its 200-day moving average is $73.59. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 12-month low of $21.92 and a 12-month high of $84.91.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.15). Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. The business had revenue of $104.44 million for the quarter, compared to analyst estimates of $102.31 million. On average, sell-side analysts predict that Insmed Incorporated will post -4.56 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.